{"entity":{"id":"nct05883956","kind":"trial","name":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","aka":["PREFER-HMA"],"tldr":"A phase 3 trial of Azacitidine and Decitabine in myelodysplastic syndromes / neoplasms, run by Otsuka Australia Pharmaceutical Pty Ltd, active and no longer recruiting.","summary":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia is a phase 3 interventional study registered as NCT05883956 by Otsuka Australia Pharmaceutical Pty Ltd, with 13 participants enrolled, started 2023-12-20 and due to reach its primary completion in 2024-12-06. Interventions recorded: Subcutaneous azacitidine and Oral decitabine/cedazuridine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05883956","url":"https://clinicaltrials.gov/study/NCT05883956"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds","mds-higher-risk"],"sections":[],"technologies":["cytotoxic-chemotherapy","epigenetic-drugs"],"targets":[],"drugs":["azacitidine","decitabine"],"companies":["otsuka"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05883956","phase":"3","setting":"A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","sponsor":"Otsuka Australia Pharmaceutical Pty Ltd","started":"2023-12-20","startedType":"actual","enrolled":13,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05883956/","neighbours":{"cancer":[{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/"}],"company":[{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/"}]}}